Clinical trial
A Long-Term, Open-Label, Study on Schizophrenia
NCT01129674
Study timeline
Study start (unknown)2010-06-01Date precision: month
Registry last updated2026-09-14
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Schizophreniaunresolved
Interventions
LY2140023DRUG
OlanzapineDRUG · verified · RxNorm: olanzapine
AripiprazoleDRUG · verified · RxNorm: aripiprazole
RisperidoneDRUG · verified · RxNorm: risperidone
QuetiapineDRUG · verified · RxNorm: quetiapine
Sponsors & collaborators
Denovo Biopharma LLClead sponsor
Mapped research locations
New YorkNew York, United States1HoustonTexas, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1DallasTexas, United States1AtlantaGeorgia, United States1SeoulSouth Korea1CincinnatiOhio, United States1San DiegoCalifornia, United States1Washington D.C.District of Columbia, United States1IndianapolisIndiana, United States1AustinTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01129674 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.